A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2016
At a glance
- Drugs LFF 269 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 13 Jan 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 05 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 15 May 2014 Planned End Date changed from 1 Feb 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.